Danaher (NYSE:DHR) Releases FY 2025 Earnings Guidance

Danaher (NYSE:DHR - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 7.600-7.750 for the period, compared to the consensus estimate of 7.670. The company issued revenue guidance of -.

Danaher Stock Down 1.0 %

Danaher stock opened at $184.96 on Tuesday. Danaher has a twelve month low of $171.00 and a twelve month high of $281.70. The business has a fifty day moving average of $201.64 and a two-hundred day moving average of $226.01. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The firm has a market cap of $132.19 billion, a P/E ratio of 35.03, a P/E/G ratio of 2.66 and a beta of 0.86.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the prior year, the firm posted $2.09 EPS. On average, analysts forecast that Danaher will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.69%. This is a positive change from Danaher's previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. Danaher's dividend payout ratio is presently 24.24%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Scotiabank assumed coverage on Danaher in a research note on Monday, December 23rd. They issued a "sector perform" rating and a $265.00 price objective for the company. Barclays raised Danaher from an "equal weight" rating to an "overweight" rating and dropped their price objective for the company from $240.00 to $205.00 in a research note on Thursday, April 10th. Citigroup reaffirmed a "buy" rating on shares of Danaher in a report on Monday, April 7th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $277.00 price target (down from $299.00) on shares of Danaher in a research note on Thursday, January 30th. Finally, Raymond James reiterated a "market perform" rating on shares of Danaher in a research report on Monday, February 3rd. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $274.55.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company's stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.